News and Events, Recent News

BriaCell Closes CEO Equity Investment

BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 24, 2017) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the “Offering”) of 5,612,083 units (the “Units”) for aggregate gross proceeds to the Company in the amount of $1,346,900 […]

Recent News

BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax™ in Patients with Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – March 15, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to initiate an open-label Phase I/IIa clinical trial of BriaVaxTM in […]

News and Events, Recent News

BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms

Berkeley, CA and Vancouver, BC – March 7, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced that it has filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property portfolio underlying the Company’s current and anticipated pipeline of whole-cell cancer vaccines, […]

Recent News

BriaCell CEO Equity Investment Advances Company’s Lead Cancer Product and Pipeline Expansion

Berkeley, CA and Vancouver, BC – February 27, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the “Offering”) of 5,416,667 units of the Company (the “Units”) at a price of C$0.24 per Unit […]

News and Events, Recent News

BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVaxTM in Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – February 6, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company has submitted a Chemistry, Manufacturing, and Controls (CMC) amendment which includes the details of extensive testing performed on BriaVax™, […]